Urinary Incontinence Global Market Report 2024

The global urinary incontinence market has grown strongly in recent years. It will grow from $11.61 billion in 2023 to $12.52 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to aging population, awareness of urinary incontinence, rising prevalence of urinary incontinence, increasing access to healthcare, rising disposable incomes.

The global urinary incontinence market is expected to see strong growth in the next few years. It will grow to $16.19 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing prevalence of comorbidities, lifestyle factors, population health strategies, growing healthcare expenditures. Major trends in the forecast period include medical advancements, innovative technologies, non-invasive treatments, digital health and mhealth, innovative product designs, patient-centered care.

The increasing prevalence of urological disorders is set to provide significant impetus to the expansion of the urinary incontinence market in the near future. Urological disorders encompass a wide array of medical conditions affecting the urinary system and male reproductive organs, which includes critical components like the kidneys, bladder, ureters, urethra, prostate, and testes. This upsurge in the prevalence of urological disorders, with a particular emphasis on conditions like urinary incontinence, is driving the demand for products and treatment options designed to address these healthcare concerns. The rising awareness and diagnosis of urological disorders, in conjunction with ongoing developments in medical solutions and healthcare infrastructure, are further bolstering the growth of this market. For instance, recent data from January 2023, as reported by the American Cancer Society Inc., reveals that the estimated cases of urinary bladder cancer in the United States have reached 82,290 in 2023, signifying a 1.1% increase from the 81,400 cases recorded in 2020. This underscores the momentum behind the expansion of the urinary incontinence market, primarily driven by the growing incidence of urological disorders.

The increasing demand for minimally invasive procedures is anticipated to be a driving force for the growth of the urinary incontinence market in the foreseeable future. Minimally invasive procedures encompass surgical techniques and interventions that involve the utilization of specialized instruments and advanced technology to reduce the size and quantity of incisions required during surgery. This heightened demand for minimally invasive procedures plays a crucial role in managing urinary incontinence, offering an effective and patient-friendly approach to its treatment. Patients and healthcare providers are increasingly opting for these methods to address the condition while minimizing the impact on a patient's daily life and overall well-being. For instance, as of January 2023, reports from Intuitive Surgical Inc., a US-based manufacturer of robotic products, indicate that approximately 1,875,000 surgical procedures were performed using Vinci Surgical Systems in 2022. This reflects an impressive 18% increase compared to the approximately 1,594,000 procedures conducted with Vinci Surgical Systems in 2021. Therefore, the mounting demand for minimally invasive procedures is set to be a significant driver behind the growth of the urinary incontinence market.

The main challenge hindering the growth of the urinary incontinence market during the forecast period is the limited accessibility of effective mechanical devices for urinary incontinence. This restricted availability of reliable mechanical devices for urinary incontinence proves to be a significant impediment in the market. It can lead to a lower number of individuals seeking treatment and can result in dissatisfaction with treatment outcomes. For instance, a Health Affairs article from 2021 reported that the United States experienced at least one shortage of medical devices each year, with the highest frequency occurring in 2020. Consequently, the limited accessibility of effective mechanical devices for urinary incontinence is constraining the expansion of the urinary incontinence market.

Prominent companies within the urinary incontinence market are proactively adopting cutting-edge technologies and groundbreaking approaches to elevate patient care and enhance treatment outcomes. For instance, in July 2023, UroMems SAS, a biotechnology firm based in France, successfully carried out the implantation of the UroActive smart artificial urinary sphincter (AUS) in a female patient for the treatment of stress urinary incontinence (SUI) in women. This groundbreaking UroActive device is powered by a myoelectrical mechanical system (MEMS) meticulously engineered to address the unmet need for a definitive SUI treatment in women. The procedure was conducted with robotic assistance at La Pitié-Salpêtrière University Hospital in Paris and garnered regulatory approval from the French equivalent of the FDA. UroActive's adaptability, intelligent functionality, and minimally invasive approach collectively aim to enhance the quality of life for patients.

In February 2021, Axonics Modulation Technologies, Inc., a US-based medical equipment manufacturing company, acquired Contura Ltd. for $200 million. The acquisition of Contura Ltd. allowed Axonics Modulation Technologies to expand its offerings, enhance its value proposition to customers and leverage its existing commercial footprint to address the underpenetrated stress urinary incontinence (SUI) market with a clinically differentiated solution. Contura Ltd. is a UK-based medical technology company specializing in developing urinary health treatment products.

Major players in the urinary incontinence market are Cardinal Health Inc., Johnson and Johnson, Medtronic PLC, Eli Lilly and Company, Asahi Kasei Corporation, Becton Dickinson and Company (C.R. Bard Inc.), Teva Pharmaceutical Industries Ltd., Berry Global Inc., Boston Scientific Corporation, Mylan N.V., Sun Pharmaceutical Industries Ltd., Domtar Corporation, Cook Medical Inc., Aurobindo Pharma Ltd., Coloplast AIS, Teleflex Incorporated, Apotex Inc., Zydus Lifesciences Limited, ConvaTec Group PLC, Cook Group Inc., Torrent Pharmaceuticals Ltd., Alennbic Pharmaceuticals Limited, Laborie Medical Technologies Corp., NeoTract Inc., Ethicon Inc., Promedon GmbH, Caldera Medical Inc.

North America was the largest region in the urinary incontinence market in 2023. The regions covered in urinary incontinence report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urinary incontinence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of urinary incontinence include urge incontinence, stress incontinence, overflow incontinence, and functional incontinence. Urge incontinence, also known as overactive bladder, is typified by a sudden and intense urge to urinate that is difficult to control. This type is typically managed through medications that help calm and control bladder muscles, along with behavioral techniques such as bladder training and lifestyle adjustments. Various treatments, including medications and medical devices, are administered through oral, parenteral, and other routes to address urinary incontinence. Diagnostic tools and services, such as physical examinations, pad tests, urodynamic testing, cystoscopy, stress tests, ultrasound scans, and urine samples, are provided by a range of end users, including hospitals, specialty clinics, homecare services, and others.

This report provides urinary incontinence market statistics, including urinary incontinence industry global market size, regional shares, competitors with a urinary incontinence market share, detailed urinary incontinence market segments, market trends and opportunities and any further data you may need to thrive in the urinary incontinence industry. This urinary incontinence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary incontinence market includes revenues earned by entities by providing medical diagnosis and evaluation, medication and surgical interventions, pelvic floor muscle training and physical therapy, behavioral therapies and bladder training and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary incontinence market also includes sales of electrical stimulation devices, foley catheters, antimicrobial foley catheters and urethral bulking agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.